188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas

Inclusion Criteria:

* Adult over 18,
* WHO performance status ≤ 2,
* Hepatocellular carcinoma histologically or cytologically proven, or association of liver tumor with chronic hepatopathy and AFP \> 400 ng/ml, or tumorous hepatic formation considered as hypervascularised by at least 2 methods of imaging in cirrhotic patient, Non operable, non resectable, non transplantable, non accessible to percutaneous treatment tumor,
* Measurable tumor, uni- or multinodular, taking up less than 50% of hepatic volume,
* Stage A to C of the BCLC classification (or stage 0 to 4 of the CLIP) with:

  * No thrombosis of the portal vein, therapeutic escape or intolerance causing the end of the treatment or contraindication to sorafenib
  * If thrombosis of the portal vein, therapeutic escape to Lipiocis,
* Possibility of treatment by intra-arterial radiotherapy over a decision of a Multidisciplinary Committee,
* Written informed consent

Exclusion Criteria:

* Patient with a stage ≥ 3 toxicity of the CTCAE version 4
* Stage D of the classification BCLC
* Acute impairment of hepatic functions (Child-Pugh B9 or C)
* Grade III Hepatocarcinoma of the Okuda classification
* Encephalopathy with troubles even moderated of cognitive functions
* Advanced chronic respiratory insufficiency
* Creatinine clearance \< 55 ml/min, polynuclear neutrophils \< 1500 G/L, platelets \< 50 G/L, prothrombin \< 40% (INR \> 2,3)
* Contraindication to the intra-arterial administration
* Patients who can't be followed up for psychological or geographic reasons
* Patients dependant on another person for daily care
* Urinary incontinence
* Progressive cancer
* Pregnant or breastfeeding woman, or not using adequate effective contraception method